Search Login Register
adalimumab
(Humira)
Summary
Description:
a fully humanized anti-TNFalpha monoclonal antibody
Also Known As:
Humira; Abbott brand of adalimumab; D2E7 antibody
Networked: 2321
relevant articles (461 outcomes,
464 trials/studies)
for this Drug
Key Diseases for which adalimumab is
Relevant
-
Crohn Disease (Crohn's Disease)
:
129 outcomes 85 studies in 460 results
-
Psoriasis (Pustulosis Palmaris et Plantaris)
:
96 outcomes 102 studies in 462 results
-
Rheumatoid Arthritis
:
60 outcomes 120 studies in 572 results
-
Ulcerative Colitis
:
35 outcomes 24 studies in 124 results
-
Ankylosing Spondylitis
:
30 outcomes 35 studies in 137 results
Show All >>
Drugs Related to adalimumab
-
infliximab (Remicade)
-
TNFR-Fc fusion protein (etanercept)
-
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
-
Methotrexate (Mexate)
-
CDP870
-
golimumab
-
monoclonal antibody CNTO 1275 (CNTO 1275)
-
Phenobarbital (Luminal)
-
Azathioprine (Imuran)
-
Antirheumatic Agents (DMARD)
Show All >>
Therapies Related to adalimumab
-
Biological Therapy
-
Drug Therapy (Chemotherapy)
-
Retreatment
-
Aftercare (After-Treatment)
-
Injections
Show All >>
CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.